Literature DB >> 15070694

Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack?

Christian Demanet1, Arend Mulder, Veronique Deneys, Maria J Worsham, Piet Maes, Frans H Claas, Soldano Ferrone.   

Abstract

Human leukocyte antigen (HLA) class I antigen defects may have a negative impact on the growing application of T-cell-based immunotherapeutic strategies for treatment of leukemia. Therefore in the present study, taking advantage of a large panel of HLA class I allele-specific human monoclonal antibodies, we have compared HLA class I antigen expression on leukemic cells with that on autologous and allogeneic normal cells. Down-regulation of HLA-A and/or -B allospecificities was present in the majority of the patients studied. However, down-regulation did not affect all HLA class I alleles uniformly, but was almost exclusively restricted to HLA-A allospecificities and to HLA-B allospecificities which belong to the HLA-Bw6 group. The latter allospecificities, at variance from those that belong to the HLA-Bw4 group, do not modulate the interactions of leukemic cells with natural killer (NK) cells. Therefore, our results suggest that the selective down-regulation of HLA-A and HLA-Bw6 allospecificities associated with HLA-Bw4 preservation provides leukemic cells with an escape mechanism not only from cytotoxic T lymphocytes (CTLs), but also from NK cells. As a result T-cell-based immunotherapeutic strategies for leukemia should utilize HLA-Bw4 alloantigens as restricting elements since a selective HLA-Bw4 allele loss would provide leukemic cells with an escape mechanism from CTLs, but would increase their susceptibility to NK cell-mediated lysis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15070694     DOI: 10.1182/blood-2003-07-2500

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

1.  Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy.

Authors:  Caroline Veuillen; Thérèse Aurran-Schleinitz; Rémy Castellano; Jérôme Rey; Françoise Mallet; Florence Orlanducci; Laurent Pouyet; Sylvaine Just-Landi; Diane Coso; Vadim Ivanov; Xavier Carcopino; Réda Bouabdallah; Yves Collette; Cyril Fauriat; Daniel Olive
Journal:  J Clin Immunol       Date:  2012-02-09       Impact factor: 8.317

2.  Major histocompatibility complex class i and tumour immuno-evasion: how to fool T cells and natural killer cells at one time.

Authors:  D Fruci; M Benevolo; L Cifaldi; S Lorenzi; E Lo Monaco; E Tremante; P Giacomini
Journal:  Curr Oncol       Date:  2012-02       Impact factor: 3.677

3.  A novel method for KIR-ligand typing by pyrosequencing to predict NK cell alloreactivity.

Authors:  Gong Yun; Jakub Tolar; Anton K Yerich; Steven G E Marsh; James Robinson; Harriet Noreen; Bruce R Blazar; Jeffrey S Miller
Journal:  Clin Immunol       Date:  2007-04-18       Impact factor: 3.969

Review 4.  Potential role of natural killer cell receptor-expressing cells in immunotherapy for leukemia.

Authors:  Junji Tanaka; Masahiro Asaka; Masahiro Imamura
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

5.  Mechanisms of malignant glioma immune resistance and sources of immunosuppression.

Authors:  German G Gomez; Carol A Kruse
Journal:  Gene Ther Mol Biol       Date:  2006

6.  Erroneous HLA typing as a result of acquired uniparental disomy in a patient with acute lymphoblastic leukaemia in peripheral blood complete remission.

Authors:  Andrea Bontadini; Sandra Iannelli; Fiorenza Fruet; Simonetta Capelli; Riccardo Masetti; Valérie Dubois; Jean-Marie Tiercy; Arcangelo Prete
Journal:  Blood Transfus       Date:  2015-01-29       Impact factor: 3.443

7.  Analysis of HLA class Ia transcripts in human leukaemias.

Authors:  Durjoy Majumder; Debasis Bandyopadhyay; Sarmila Chandra; Ashis Mukhopadhayay; Nandini Mukherjee; Subir K Bandyopadhyay; Subrata Banerjee
Journal:  Immunogenetics       Date:  2005-09-29       Impact factor: 2.846

8.  Fine-mapping of HLA associations with chronic lymphocytic leukemia in US populations.

Authors:  Loren Gragert; Stephanie Fingerson; Mark Albrecht; Martin Maiers; Matt Kalaycio; Brian T Hill
Journal:  Blood       Date:  2014-09-17       Impact factor: 22.113

9.  Generation and preclinical characterization of a Fc-optimized GITR-Ig fusion protein for induction of NK cell reactivity against leukemia.

Authors:  Benjamin Joachim Schmiedel; Antje Werner; Julia Steinbacher; Tina Nuebling; Corina Buechele; Ludger Grosse-Hovest; Helmut Rainer Salih
Journal:  Mol Ther       Date:  2013-02-05       Impact factor: 11.454

10.  ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor Immunopeptidome.

Authors:  Claire Y Oh; Martin G Klatt; Christopher Bourne; Tao Dao; Megan M Dacek; Elliott J Brea; Sung Soo Mun; Aaron Y Chang; Tatyana Korontsvit; David A Scheinberg
Journal:  Cancer Immunol Res       Date:  2019-09-20       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.